National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D: Prospects for Immunizing Against Coccidioidomycosis." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
183
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Appendix D
PROSPECTS FOR IMMUNIZING AGAINST COCCIDIOIDOMYCOSIS

Disease Description

Coccidioidomycosis (valley fever, San Joaquin fever) is caused by the dimorphic fungus Coccidioides immitis. This fungus grows in the soil and produces spores (arthroconidia), which are carried by air currents and inhaled by humans and lower animals. In the united States, Coccidioidomycosis is endemic to California, Arizona, New Mexico, parts of Nevada and Utah, and southwestern Texas.

The population of the endemic areas is estimated to be about 20,000,000 (Chin, personal communication, 1983; Pappagianis, personal communication, 1983), but temporary visitors to these areas also may develop the disease. Individuals in occupations that involve working with the soil (e.g., agriculture, construction, and oil drilling) appear to be at increased risk (Chin, personal communication, 1983; Cox, 1983; Pappagianis, personal communication, 1983). Morbidity and mortality rates also are higher among certain racial and ethnic groups: black, Asian (especially Filipino), and Mexican males are at greater risk of disseminated disease than white males, for example (Pappagianis, 1980). The disease affects all age groups; the highest incidence is in males over the age of 25.

Less than half of those who become infected develop clinical signs of disease. The primary lesion is usually pulmonary. In those who become ill, clinical symptoms of fever, malaise, cough, and chest pain follow an incubation period of 7 to 28 days (typically 10 to 16 days). Night sweats and anorexia may occur also. The disease is usually self-limited, particularly in adults. A few individuals may develop residual cavitary disease, and sometimes nodules or pulmonary abscesses. The pulmonary cavities usually heal spontaneously. Chronic progressive pulmonary disease, resembling histoplasmosis or tuberculosis, occurs in a small number of patients.

Allergic manifestations also appear in some cases. Erythema nodosum or erythema multiforme may develop a few days or a few weeks

The advice and assistance of D.Pappagianis and R.Cox in the preparation of this appendix are gratefully acknowledged. The committee assumes full responsibility for any judgments or assumptions.

Page
183
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 183

OCR for page 184

OCR for page 185

OCR for page 186

OCR for page 187

OCR for page 188

OCR for page 189

OCR for page 190

OCR for page 191

OCR for page 192

OCR for page 193

OCR for page 194

OCR for page 195

OCR for page 196

OCR for page 197